Longtime drug developer Suma Krishnan was 51 when she cofounded Krystal Biotech. Now the company has one gene therapy on the market and more in the works. https://t.co/4iMhKpwYT9 ...

Company Overview - Krystal Biotech 由 Suma Krishnan 在 51 岁时共同创立 [1] - Krystal Biotech 目前已有一种基因疗法上市，并有更多疗法正在研发中 [1] Drug Development - Krystal Biotech 是一家药物开发公司 [1] - Krystal Biotech 有基因疗法产品在市场上 [1]

Sarepta is cutting more than one-third of its workforce and will add a black box warning label to its gene therapy for a fatal muscle disorder after two patient deaths raised doubts about the future of the company https://t.co/FHYwnWd7ml ...

Core Insights - The report provides a comprehensive analysis of global biologics sales, including various categories such as cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, and RNA-based drugs [1][3][5] - It highlights sales data, growth trends, and rankings of top biologics, making it essential for biopharma professionals, investors, and market analysts [1][2] Sales Data Overview - The report compiles and analyzes sales data for originator recombinant therapeutic proteins and antibodies for the year 2024, including publicly available data for biosimilars and new biologic modalities [3][5] - Sales data from 2012 to 2024 are summarized, showing growth rates and the percentage of antibody sales relative to total biologics sales [5] Product Categories - Individual product sales data are categorized into groups such as cancer antibodies, non-TNF anti-inflammatory mAbs, cardiometabolic antibodies, and more [9][10] - Target-specific sales data for cancer antibodies and non-TNF anti-inflammatory antibodies are calculated for 2024, covering various therapeutic areas [7][12] Market Trends - The report emphasizes the commercial success of novel antibody drug modalities, including antibody-drug conjugates and bispecific antibodies, with sales and growth rates presented from 2012 to 2024 [16] - A total of 75 innovator therapeutic antibodies and proteins achieved blockbuster status in 2024, each exceeding sales of US$ 1 billion [16] Company Rankings - A ranking list of the top 30 companies regarding biologics sales in 2024 is provided, along with company-specific sales data for biosimilars from 2020 to 2023 [16] - The report includes detailed sales data for various biologic products, highlighting the competitive landscape within the industry [14][16]